Lipid based nanocarriers for effective drug delivery and treatment of diabetes associated liver fibrosis

Shubham A. Salunkhe, Deepak Chitkara, Ram I. Mahato, Anupama Mittal

Research output: Contribution to journalArticlepeer-review

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a cluster of several liver diseases like hepatic steatosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver (NAFL), liver fibrosis, and cirrhosis which may eventually progress to liver carcinoma. One of the primary key factors associated with the development and pathogenesis of NAFLD is diabetes mellitus. The present review emphasizes on diabetes-associated development of liver fibrosis and its treatment using different lipid nanoparticles such as stable nucleic acid lipid nanoparticles, liposomes, solid lipid nanoparticles, nanostructured lipid carriers, self-nanoemulsifying drug delivery systems, and conjugates including phospholipid, fatty acid and steroid-based. We have comprehensively described the various pathological and molecular events linking effects of elevated free fatty acid levels, insulin resistance, and diabetes with the pathogenesis of liver fibrosis. Various passive and active targeting strategies explored for targeting hepatic stellate cells, a key target in liver fibrosis, have also been discussed in detail in this review.

Original languageEnglish (US)
Pages (from-to)394-415
Number of pages22
JournalAdvanced Drug Delivery Reviews
Volume173
DOIs
StatePublished - Jun 2021

Keywords

  • Conjugates
  • Diabetes
  • Lipid nanoparticles
  • Liposomes
  • Liver fibrosis
  • Liver targeting
  • NAFLD
  • NASH
  • NLCs
  • SLNs

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Lipid based nanocarriers for effective drug delivery and treatment of diabetes associated liver fibrosis'. Together they form a unique fingerprint.

Cite this